Heart, Lung and Circulation
Volume 15, Issue 1 , Pages 56-58 , February 2006

Pre-operative Use of Levosimendan in Two Patients with Severe Aortic Stenosis and Left Ventricular Dysfunction

  • David L. Prior, MBBS, BMedSc, PhD, FRACP, DDU

      Affiliations

    • Cardiac Investigation Unit, St Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, Vic. 3065, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +613 9288 4423; fax: +613 9288 4422.
    • ,
  • Brendan D. Flaim, MBBS

      Affiliations

    • Cardiac Investigation Unit, St Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, Vic. 3065, Australia
    • ,
  • Andrew I. MacIsaac, MBBS, MD, FRACP

      Affiliations

    • Cardiac Investigation Unit, St Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, Vic. 3065, Australia
    • ,
  • Michael Y. Yii, MS, FRACS

      Affiliations

    • Department of Cardiothoracic Surgery, St Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, Vic. 3065, Australia

References 

  1. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249–259
  2. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141–2147
  3. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81–86
  4. Carabello BA, Stewart WJ, Crawford FA. Aortic valve disease. In:  Topol EJ editors. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven; 1998;p. 533–555
  5. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756–1763
  6. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34:219–228
  7. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202
  8. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: Part 2. Circulation. 2001;104:3158–3167

PII: S1443-9506(05)00058-2

doi: 10.1016/j.hlc.2005.03.008

Heart, Lung and Circulation
Volume 15, Issue 1 , Pages 56-58 , February 2006

Article Tools

* Image Usage & Resolution